Statin Use Is Associated With Reduced Heart Failure and Risk of Death in Non-Hodgkin Lymphoma.
作者信息
Chen Chao-Yu, Chang Wei-Ting, Lin Hui-Wen, Lin Sheng-Hsiang, Li Yi-Heng
机构信息
National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Madou Sin-Lau Hospital, Tainan, Taiwan.
出版信息
JACC CardioOncol. 2024 Feb 20;6(1):133-135. doi: 10.1016/j.jaccao.2023.12.005. eCollection 2024 Feb.
Abstract
摘要
相似文献
1
Statin Use Is Associated With Reduced Heart Failure and Risk of Death in Non-Hodgkin Lymphoma.他汀类药物的使用与非霍奇金淋巴瘤患者心力衰竭的减轻及死亡风险的降低相关。
JACC CardioOncol. 2024 Feb 20;6(1):133-135. doi: 10.1016/j.jaccao.2023.12.005. eCollection 2024 Feb.
2
Associations between statin use and non-Hodgkin lymphoma (NHL) risk and survival: a meta-analysis.他汀类药物使用与非霍奇金淋巴瘤（NHL）风险及生存之间的关联：一项荟萃分析。
Hematol Oncol. 2017 Jun;35(2):206-214. doi: 10.1002/hon.2265. Epub 2015 Oct 20.
3
Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.在利妥昔单抗时代治疗的 16098 例非霍奇金淋巴瘤或慢性淋巴细胞白血病患者中，他汀类药物的使用与生存情况。
Br J Haematol. 2021 Nov;195(4):552-560. doi: 10.1111/bjh.17733. Epub 2021 Jul 31.
4
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.一线使用环磷酰胺、阿霉素、长春新碱和泼尼松（CHOP）或CHOP联合利妥昔单抗（R-CHOP）治疗的非霍奇金淋巴瘤患者的心血管不良事件：一项系统评价和荟萃分析。
Lancet Haematol. 2020 Apr;7(4):e295-e308. doi: 10.1016/S2352-3026(20)30031-4. Epub 2020 Mar 2.
5
Previous Exposure to Statin May Reduce the Risk of Subsequent Non-Hodgkin Lymphoma: A Nationwide Population-Based Case-Control Study.既往使用他汀类药物可能降低后续非霍奇金淋巴瘤的风险：一项基于全国人口的病例对照研究。
PLoS One. 2015 Oct 1;10(10):e0139289. doi: 10.1371/journal.pone.0139289. eCollection 2015.
6
Associations between statin use and risk of non-Hodgkin lymphomas by subtype.他汀类药物使用与非霍奇金淋巴瘤亚型风险的关联。
Int J Cancer. 2018 Aug 15;143(4):971-979. doi: 10.1002/ijc.31373. Epub 2018 Mar 30.
7
Statin therapy and risks for death and hospitalization in chronic heart failure.他汀类药物治疗与慢性心力衰竭患者的死亡及住院风险
JAMA. 2006 Nov 1;296(17):2105-11. doi: 10.1001/jama.296.17.2105.
8
Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis.侵袭性非霍奇金淋巴瘤的移植前氟代脱氧葡萄糖正电子发射断层扫描：系统评价与荟萃分析
Eur J Haematol. 2017 Apr;98(4):337-347. doi: 10.1111/ejh.12837. Epub 2017 Jan 23.
9
Statin exposure and risk of cancer in people with and without HIV infection.他汀类药物暴露与 HIV 感染者和非感染者癌症风险的关系。
AIDS. 2021 Feb 2;35(2):325-334. doi: 10.1097/QAD.0000000000002748.
10
Statin therapy is associated with lower mortality among patients with severe heart failure.他汀类药物治疗与重度心力衰竭患者的较低死亡率相关。
Am J Cardiol. 2004 May 1;93(9):1124-9. doi: 10.1016/j.amjcard.2004.01.039.
本文引用的文献
1
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.阿托伐他汀治疗蒽环类药物相关心脏功能障碍：STOP-CA 随机临床试验。
JAMA. 2023 Aug 8;330(6):528-536. doi: 10.1001/jama.2023.11887.
2
Association of Statin Use With Cancer- and Noncancer-Associated Survival Among Patients With Breast Cancer in Asia.亚洲乳腺癌患者中他汀类药物使用与癌症相关和非癌症相关生存的关系。
JAMA Netw Open. 2023 Apr 3;6(4):e239515. doi: 10.1001/jamanetworkopen.2023.9515.
3
Influence of Statins on the Survival Outcomes of Patients with Diffuse Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.他汀类药物对弥漫性大 B 细胞淋巴瘤患者生存结局的影响：系统评价和荟萃分析。
Int J Clin Pract. 2022 Jul 30;2022:5618290. doi: 10.1155/2022/5618290. eCollection 2022.
4
The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: State-of-the-Art Review.心脏保护在癌症治疗中的作用：心脏毒性——最新综述
JACC CardioOncol. 2022 Mar 15;4(1):19-37. doi: 10.1016/j.jaccao.2022.01.101. eCollection 2022 Mar.
Zotero 插件